Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 neoadjuvant gemcitabine/cisplatin with or without nivolumab and BMS-986205 in muscle-invasive bladder cancer
NL-OMON52608Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nivolumab, linrodostat, gemcitabine and cisplatin in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by Bristol Myers Squibb. Primary endpoints: Pathologic complete response rate for Arm C versus Arm A, Event-free survival for Arm C versus Arm A and 2 more. Started Mar 2020; status: recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON52608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52608.